Therapeutic tools for dyslipidemia in peritoneal dialysis patients

Journal of Nephrology

Volumn 22, Issue 1, 2009, Pages 46-58

  Scarpioni, Roberto ^a  

^a GUGLIELMO DA SALICETO HOSPITAL   (Italy)

Author keywords

Cardiovascular risk; Chronic kidney disease; Dyslipidemia; Intraperitoneal insulin; Lipid lowering therapy; Peritoneal dialysis

Indexed keywords

AMINO ACID; ANTILIPEMIC AGENT; ATORVASTATIN; CARNITINE; CHOLESTEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICODEXTRIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PARATHYROID HORMONE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SEVELAMER; SIMVASTATIN; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; EXERCISE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; LIPOPROTEIN METABOLISM; MALNUTRITION; MINERAL DEFICIENCY; MINERAL METABOLISM; MORTALITY; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; WEIGHT REDUCTION; CHRONIC DISEASE; KIDNEY DISEASE; LIFESTYLE; RISK FACTOR;

CHRONIC DISEASE; DYSLIPIDEMIAS; HUMANS; KIDNEY DISEASES; LIFE STYLE; PERITONEAL DIALYSIS; RISK FACTORS;

EID: 66349099442     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. US Renal Data System. USRDS 1995 annual data report: causes of death. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:79-89.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
3. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(4 Suppl 3):S22-S60.
4. Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int. 2006;26:523-539.
5. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(Suppl 3):S142-S156.
6. Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 2007;71:1036-1043.
7. Kronenberg F, Lingenhel A, Neyer U, et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl. 2003;84:S113-S116.
8. Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P. Dialysis modalities and dyslipidemia. Kidney Int Suppl. 2003;84:S110-S112.
9. Fried L, Hutchison A, Stegmayr B, Prichard S, Bargman JM. Recommendations for the treatment of lipid disorders in patients on peritoneal dialysis: ISPD guidelines/recommendations. International Society for Peritoneal Dialysis. Perit Dial Int. 1999;19:7-16.
10. Pennel P, Rojas C, Asif A, Rossini E. Managing metabolic complications of peritoneal dialysis. Clin Nephrol. 2004;62:35-43.
11. Blumenkrantz MJ, Gahl GM, Kopple JD, et al. Protein losses during peritoneal dialysis. Kidney Int. 1981;19:593-602.
12. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M. Kinetics of peritoneal protein loss during CAPD: Part I: different characteristics for low and high molecular weight proteins. Kidney Int. 1990;37:971-979.
13. Saku K, Sasaki J, Naito S, Arakawa K. Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis. Nephron. 1989;51:220-224.
14. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol. 1992;38:271-276.
15. Anwar N, Bhatnagar D, Short CD, et al. Serum lipoprotein(a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1993;8:71-74.
16. De Sain-Van Der Velden MG, Kaysen GA, Barrett HA, et al. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int. 1998;53:994-1001.
17. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M. Kinetics of peritoneal protein loss during CAPD: Part II: different characteristics for low and high molecular weight proteins. Kidney Int. 1990;37:980-990.
18. Vaziri ND, Sato T, Liang K. Molecular mechanism of altered cholesterol metabolism in in rats with spontaneous focal glomerulosclerosis. Kidney Int. 2003;63:1756-1763.
19. Scarpioni R, Paties C, Bergonzi G. Dramatic atherosclerotic vascular burden in a patient with familial lecithin-cholesterol acyltransferase (LCAT) deficiency. Nephrol Dial Transplant. 2008;23:1074-1075.
20. Longenecker JC, Coresh J, Powe N, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol. 2002;13:1918-1927.
21. Epstein M, Campese V. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on renal function. Am J Kidney Dis. 2005;45:2-14.
22. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant. 1997;12:2603-2611.
23. Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant. 2006;21:2881-2892.
24. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451-459.
25. Goldberg AP, Geltman EM, Hagberg JM, et al. Therapeutic benefits of exercise training for hemodialysis patients. Kidney Int Suppl. 1983;16:S303-S309.
26. Di Paolo B, Del Rosso G, Catucci, et al. Therapeutic effects of simvastatin on hyperlipidemia in CAPD patients. ASAIO Trans. 1990;36:M578-M580.
27. Seliger SC, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:8297-8304.
28. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.
29. Matthys E, Schurgers M, Lamberigts G, et al. Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients. Atherosclerosis. 1991;86:183-192.
30. Marangoni R, Civardi F, Masi F, Cimino R, Maltagliati L, Romei Longhena G. Dyslipidemia in patients undergoing continuous ambulatory peritoneal dialysis: pharmacological therapy (simvastatin) versus hemodialysis. Perit Dial Int. 1993;13(Suppl 2):S431-S433.
31. Dimitriadis A, Antoniou S, Hatzisavvas N, Pastore F, Kaldi I, Stangou M. The effect of simvastatin on dyslipidemia in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1993;13(Suppl 2):S434-S436.
32. Wanner C, Lubrich-Birkner I, Summ O, Wieland H, Schollmeyer P. Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients. Nephron. 1992;62:40-46.
33. Akçiçek F, Ok E, Duman S, et al. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study. Adv Perit Dial. 1996;12:261-265.
34. Hufnagel G, Michel C, Vrtovsnik F, Queffeulou G, Kossari N, Mignon F. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. Nephrol Dial Transplant. 2000;15:684-688.
35. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis. 2002;39:283-290.
36. Harris KP, Wheeler DC, Chong CC. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int. 2002;61:1469-1474.
37. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45:473-484.
38. Robson R, Collins J, Johnson R, et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. J Nephrol. 1997;10:33-40.
39. Fellstrom B, Zannad F, Schmieder R, et al; AURORA Study Group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med. 2005;23:6-9.
40. Landray M, Baigent C, Leaper C, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006;47:385-395.
41. Lee MS, Kim SM, Kim SB, Lee SK, Park JS, Yang WS. Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients. Perit Dial Int. 1999;19:280-283.
42. Jones RG, Dibble JB, Tompkins L, et al. Effect of dietary fish oil on lipid abnormalities in patients on continuous peritoneal dialysis. Perit Dial Int. 1988;8:203-206.
43. Balaskas EV, Bamihas GI, Tourkantonis A. Management of lipid abnormalities in patients on CAPD. Perit Dial Int. 1997;17:308-309.
44. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol. 2002;13:708-714.
45. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int. 1995;48:188-198.
46. Albright RK, Kram BW, White RP. Carnitine status of continuous ambulatory peritoneal dialysis patients. Lancet. 1982;2:218-219.
47. Marco M, Craver L, Betriu A, Belart M, Fibla J, Fernández E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int. 2003;63(Suppl 85):S111-S114.
48. Achinger SG, Ayus JC. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int Suppl. 2005;95:S37-S42.
49. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J. 2005;149:820-825.
50. Katopodis KP, Andrikos EK, Gouva CD, et al. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int. 2006;26:320-327.
51. Siamopoulos KC, Gouva C, Katopodis KP, et al. Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD. Am J Kidney Dis. 2006;48:242-249.
52. Marsillach J, Martinez-Vea A, Marcas L, et al. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Clin Exp Pharmacol Physiol. 2007;34:347-349.
53. Kagan A, Haran N, Shuali N, Leshinsky L, Rapoport J. Serum apolipoprotein A1 levels in peritoneal dialysis patients are affected by erythropoietin therapy. Perit Dial Int. 1999;19:486-490.
54. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int. 1994;46:496-503.
55. Opatrnà S, Opatrny K Jr, Senft V, Stehlík F, Racek J. The effect of icodextrin-based dialysis solution on selected metabolic parameters in CAPD patients [abstract]. Perit Dial Int. 2001;21(Suppl 2):S98.
56. Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant. 2006;21:494-498.
57. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int. 2001;21:275-288.
58. Sisca S, Maggiore U. Beneficial effect of icodextrin on the hypertriglyceridemia of CAPD patients. Perit Dial Int. 2002;22:727-729.
59. Plum J, Gentile S, Verger C, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis. 2002;39:862-871.
60. Grzegorzewska AE, Mariak I, Dobrowolska-Zachwieja A, Szajdak L. Effects of amino acid dialysis solution on the nutrition of continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999;19:462-470.
61. Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif. 2005;23:303-310.
62. Scarpioni L, Ballocchi S, Scarpioni R, Cristinelli L. Peritoneal dialysis in diabetics: optimal insulin therapy on CAPD: intraperitoneal versus subcutaneous treatment. Perit Dial Int. 1996;16(Suppl 1):S275-S278.
63. Scarpioni L, Ballocchi S, Castelli A, Scarpioni R. Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis; comparison of intraperitoneal and subcutaneous administration. Perit Dial Int. 1994;14:127-131.
64. Bagdade JD, Kelley DE, Henry RR, Eckel RH, Ritter MC. Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipase activities in NIDDM. Diabetes. 1997;46:414-420.
65. Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol. 2002;13(Suppl 1):S92-S96.
66. Nevalainen P, Lahtela JT, Mustonen J, Pasternack A. The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients. Nephrol Dial Transplant. 1997;12:145-150.
67. Khanna R, Oreopoulos DG. Peritoneal dialysis in diabetic end-stage renal disease. J Diabet Complications. 1989;3:12-17.
68. Harris K, Thomas M, Short C, Moore R. Assessment of the efficiency of treatment of dyslipidemia in renal outpatients. J Nephrol. 2002;15:263-269.
69. Ritz E, Dikow R, Gross ML. Dialysis, cardiovascular disease, and the future. Hemodial Int. 2007;11(Suppl 1):S2-S11.